¼¼°èÀÇ µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ½ÃÀå
Duchenne Muscular Dystrophy Drugs
»óǰÄÚµå : 1648907
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 220 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ¼¼°è ½ÃÀå, 2030³â±îÁö 297¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇÒ Àü¸Á

2024³â 44¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È CAGR 37.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 297¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Exon Skipping ¿ä¹ýÀº CAGR 42.6%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 197¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ºÅ×·ÎÀÌµå ¿ä¹ýÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 26.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 18¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 43.6%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â 18¾ï ´Þ·¯ ±Ô¸ð·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 24¾ï ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 43.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ºÐ¼® ±â°£ µ¿¾È °¢°¢ 30.9%¿Í 30.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 32.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ°ú ±× ¿µÇâÀº?

µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ(DMD)Àº ÁøÇ༺ ±ÙÀ° ÅðÇà°ú ±Ù·Â ÀúÇϸ¦ Ư¡À¸·Î ÇÏ´Â ½É°¢ÇÑ À¯Àü¼º ÁúȯÀÔ´Ï´Ù. ÁÖ·Î ³²ÀÚ¾ÆÀÌ¿¡°Ô ¹ßº´Çϸç, º¸Åë 2-5¼¼ »çÀÌ¿¡ Áõ»óÀÌ ³ªÅ¸³³´Ï´Ù. ÀÌ ÁúȯÀº ±ÙÀ° ±â´É¿¡ ÇʼöÀûÀÎ µð½ºÆ®·ÎÇÉ À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. µð½ºÆ®·ÎÇÉÀÌ °áÇÌµÇ¸é ±ÙÀ° ¼¶À¯°¡ ¼Õ»óµÇ°í °á±¹ Áö¹æ°ú °áÇÕÁ¶Á÷À¸·Î ´ëüµÇ¸ç, DMD°¡ ÁøÇàµÇ¸é º¸Çà Àå¾Ö, È£Èí±â ¹× ½ÉÀå ÇÕº´ÁõÀ» À¯¹ßÇÏ°í ¿¹Èİ¡ ½É°¢ÇÏ°Ô ³ªºüÁý´Ï´Ù. ȯÀÚ¿Í °¡Á·¿¡°Ô ¹ÌÄ¡´Â ¿µÇâÀº ¸Å¿ì ½É°¢Çϸç, Áö¼ÓÀûÀÎ ÀÇ·áÀû Ä¡·á¿Í Áö¿øÀÌ ÇÊ¿äÇÕ´Ï´Ù.

Ä¡·á Á¢±Ù¹ýÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·á¹ýÀº À¯ÀüÀÚ Ä¡·á, ºÐÀÚ Ä¡·áÁ¦, ´ëÁõ¿ä¹ý µîÀÇ ¹ßÀüÀ¸·Î ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¿ª»çÀûÀ¸·Î ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å´Â DMD Ä¡·áÀÇ Áß½ÉÀÌ µÇ¾î ±ÙÀ°ÀÇ ÅðÈ­¸¦ ´ÊÃß´Â µ¥ µµ¿òÀÌ µÇ¾ú½À´Ï´Ù. ±×·¯³ª ÃÖ±Ù¿¡´Â DMDÀÇ ±Ùº»ÀûÀÎ À¯ÀüÀû ¿øÀÎÀ» ÇØ°áÇϱâ À§ÇÑ À¯ÀüÀÚ Ä¡·á¿Í ¿¢¼Õ ½ºÅ°ÇÎ ¾à¹°ÀÌ Å©°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀº °á¼ÕµÈ µð½ºÆ®·ÎÇÉ À¯ÀüÀÚ¸¦ º¹±¸Çϰųª ´ëüÇϵµ·Ï ¼³°èµÇ¾î º¸´Ù È¿°úÀûÀ̰í Àå±âÀûÀÎ Ä¡·á È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹°¸®Ä¡·á, È£Èí °ü¸® ¹× ½ÉÀå °ü¸®¿Í °°ÀºÁöÁö ¿ä¹ýÀº »îÀÇ ÁúÀ» °³¼±Çϰí Áúº´ ÇÕº´ÁõÀ» °ü¸®ÇÏ´Â µ¥ °è¼Ó Áß¿äÇÕ´Ï´Ù.

ÀÓ»ó½ÃÇè°ú ¾à»ç¹ý ½ÂÀÎÀº ¾î¶² ¿ªÇÒÀ» Çϴ°¡?

ÀÓ»ó½ÃÇè°ú ½Ä¾àó ½ÂÀÎÀº µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇÏ°í »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. »õ·Î¿î Ä¡·áÁ¦ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇϱâ À§Çؼ­´Â ¾ö°ÝÇÑ ÀÓ»ó½ÃÇèÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»ó½ÃÇèÀº ¿©·¯ ´Ü°è¿¡ °ÉÃÄ ÁøÇàµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ¿¬±¸ÀÚ, ÀÇ·áÁø, ȯÀÚÀÇ Çù·ÂÀÌ ÇÊ¿äÇϸç, FDA ¹× EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº ½Å¾àÀÇ Æò°¡ ¹× ½ÂÀο¡ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÏ¿© ½Å¾àÀÌ ¾ö°ÝÇÑ ¾ÈÀü¼º ¹× À¯È¿¼º ±âÁØÀ» ÃæÁ·ÇÏ´ÂÁö È®ÀÎÇÕ´Ï´Ù. DMD¿Í °°Àº Èñ±ÍÁúȯÀÇ Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ Á¶±â ½ÂÀÎ °æ·Î¿Í Èñ±ÍÁúȯ Ä¡·áÁ¦ ÁöÁ¤ÀÌ Á¾Á¾ Ȱ¿ëµÇ¾î ȯÀÚ¿¡°Ô À¯¸ÁÇÑ Ä¡·á¹ýÀ» Á¶±â¿¡ Á¦°øÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀº ¹«¾ùÀΰ¡?

µà¼ÏÇü ±ÙÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº À¯ÀüÀÚ ¿¬±¸ÀÇ ¹ßÀü, ÀÚ±Ý ¹× ÅõÀÚ Áõ°¡, Áúº´ À¯º´·ü Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. À¯ÀüÀÚ ÆíÁý°ú ºÐÀÚ»ý¹°ÇÐ ºÐ¾ßÀÇ Çõ½ÅÀº º¸´Ù Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÎ Ä¡·á¹ýÀ» À§ÇÑ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. Á¤ºÎ, ºñ¿µ¸® ´Üü ¹× Á¦¾àȸ»çÀÇ ÀÚ±Ý Áö¿ø Áõ°¡´Â ¿¬±¸ °³¹ß ³ë·ÂÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, DMD¿¡ ´ëÇÑ Àνİú Áø´ÜÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á¸¦ ¿øÇϴ ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°øÇÐ ±â¾÷°ú Çмú ±â°üÀÇ Çù·ÂÀº Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Èñ±ÍÁúȯ Ä¡·áÁ¦ÀÇ Á¶±â ½ÂÀÎÀ» À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê°¡ ÀÖ´Â ±ÔÁ¦ ȯ°æÀº DMD ȯÀÚÀÇ ¿¹ÈÄ °³¼±¿¡ ´ëÇÑ Èñ¸ÁÀ» °¡Á®´ÙÁÖ¸ç ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ºÎ¹®(¿¢¼Õ½ºÅµÇÎ, ½ºÅ×·ÎÀÌµå ¿ä¹ý, µ¹¿¬º¯ÀÌ ¾ïÁ¦, ±âŸ ºÎ¹®)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 38°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Duchenne Muscular Dystrophy Drugs Market to Reach US$29.7 Billion by 2030

The global market for Duchenne Muscular Dystrophy Drugs estimated at US$4.4 Billion in the year 2024, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Exon Skipping Therapy, one of the segments analyzed in the report, is expected to record a 42.6% CAGR and reach US$19.7 Billion by the end of the analysis period. Growth in the Steroid Therapy segment is estimated at 26.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 43.6% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 43.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 30.9% and 30.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 32.5% CAGR.

Global Duchenne Muscular Dystrophy Drugs Market - Key Trends & Drivers Summarized

What Is Duchenne Muscular Dystrophy and Its Impact?

Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, with symptoms typically appearing between the ages of two and five. The disease is caused by mutations in the dystrophin gene, which is essential for muscle function. Without dystrophin, muscle fibers are damaged and eventually replaced by fat and connective tissue. The progression of DMD leads to loss of ambulation, respiratory and cardiac complications, and significantly reduced life expectancy. The impact on patients and their families is profound, necessitating ongoing medical care and support.

How Are Treatment Approaches Evolving?

Treatment approaches for Duchenne Muscular Dystrophy are evolving rapidly, with advancements in genetic therapies, molecular drugs, and symptomatic treatments. Historically, corticosteroids have been the mainstay of DMD treatment, helping to slow muscle degeneration. However, recent years have seen significant progress in gene therapy and exon-skipping drugs, which aim to address the underlying genetic causes of DMD. These innovative therapies are designed to restore or replace the defective dystrophin gene, offering the potential for more effective and long-lasting treatment outcomes. Additionally, supportive therapies such as physical therapy, respiratory care, and cardiac management remain crucial for improving quality of life and managing disease complications.

What Role Do Clinical Trials and Regulatory Approvals Play?

Clinical trials and regulatory approvals are pivotal in the development and availability of new treatments for Duchenne Muscular Dystrophy. Rigorous clinical trials are essential for demonstrating the safety and efficacy of new therapies. These trials often involve multiple phases and require collaboration between researchers, healthcare providers, and patients. Regulatory bodies, such as the FDA and EMA, play a critical role in evaluating and approving new drugs, ensuring that they meet stringent safety and effectiveness standards. Accelerated approval pathways and orphan drug designations are often utilized to expedite the development of treatments for rare diseases like DMD, providing patients with earlier access to promising therapies.

What Factors Are Driving Market Growth?

The growth in the Duchenne Muscular Dystrophy drugs market is driven by several factors, including advancements in genetic research, increased funding and investment, and the rising prevalence of the disease. Technological innovations in gene editing and molecular biology are paving the way for more targeted and effective treatments. Increased funding from governments, non-profit organizations, and pharmaceutical companies is accelerating research and development efforts. The rising awareness and diagnosis of DMD are also contributing to market growth, as more patients seek treatment. Additionally, collaborations between biotech firms and academic institutions are fostering the development of innovative therapies. The regulatory environment, with initiatives to fast-track the approval of orphan drugs, is further supporting market expansion, providing hope for improved outcomes for patients with DMD.

SCOPE OF STUDY:

The report analyzes the Duchenne Muscular Dystrophy Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Exon Skipping, Steroid Therapy, Mutation Suppression, Other Segments)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â